Lianne Ten Have
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lianne Ten Have has a total of 105 co-authors. Here are the top co-authors by number of shared publications:
Anneke Ten Brinke
5 shared publicationsJacob K. Sont
5 shared publications- Anneke Ten Brinke
Department of Pulmonology, Frisius Medical Centre, Leeuwarden, the Netherlands
4 shared publications Fleur L. Meulmeester
Department of Biomedical Data Sciences, section Medical Decision Making, Leiden University Medical Centre, Leiden, The Netherlands
4 shared publications- Fleur Louise Meulmeeser
Department of Biomedical Data Sciences, Leiden University Medical Centre, Leiden, the Netherlands
4 shared publications Kim de Jong
4 shared publications
Latest Publications
- Open Access
- 1 October 2026
- Published by Elsevier in Respiratory Medicine
- Vol. 263
Davos@home: Integrating objective home monitoring into eHealth self-management support after alpine altitude climate treatment for severe asthma
- 1 October 2026
- Published by Elsevier in Respiratory Medicine
- Vol. 263
Open AccessDavos@home: Integrating objective home monitoring into eHealth self-management support after alpine altitude climate treatment for severe asthma
- Open Access
- 17 July 2026
- Published by Elsevier in SSRN Electronic Journal
Davos@home: Integrating Objective Home Monitoring into eHealth Self-management Support after Alpine Altitude Climate Treatment for Severe Asthma
Background: Severe asthma imposes substantial burden, and many patients remain uncontrolled despite guideline-based therapy. Alpine Altitude Climate Treatment (AACT) improves asthma control and quality of life, yet benefits often attenuate after returning home. eHealth-supported self-management may help sustain AACT gains and prevent post-rehabilitation relapse, though the added value of objective home monitoring devices remains unclear.Methods: In this 12-month pragmatic trial, adults with severe asthma completing AACT in Davos were randomised to eHealth self-management support with or without home monitoring devices measuring airway inflammation, lung function and activity. Randomisation was stratified by baseline fractional exhaled nitric oxide (FeNO; <25 vs ≥25 ppb). The pre-specified primary outcome was time-to-first severe exacerbation; secondary outcomes included annualised exacerbation and hospitalization rates and patient-reported outcomes.Results: Between 2022-2024, 143 patients were randomised; 130 received the allocated intervention (66 intervention, 64 control), and 105 completed follow-up. Time-to-first severe exacerbation did not differ between groups (median [IQR] intervention: 16.5 [13-23], control: 20 [16-30] weeks; log-rank p=0.93). There was a non-significant trend toward fewer annualised severe exacerbations in the intervention group (aRR 0.68, 95%CI 0.45-1.03; p=0.07). Slower ACQ-6 decline (baseline-6 months) was observed in the intervention group (β -0.50, 95%CI -0.95;-0.05; p=0.03), though this did not persist to 12 months. No effect modification by FeNO strata was observed; no intervention-related serious adverse events occurred.Conclusions: Adding home monitoring devices to eHealth self-management did not prolong time-to-first severe exacerbation or sustain clinical benefits after AACT. More personalised, clinically integrated strategies could support the transition to independent self-management.
- 17 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessDavos@home: Integrating Objective Home Monitoring into eHealth Self-management Support after Alpine Altitude Climate Treatment for Severe Asthma
Background: Severe asthma imposes substantial burden, and many patients remain uncontrolled despite guideline-based therapy. Alpine Altitude Climate Treatment (AACT) improves asthma control and quality of life, yet benefits often attenuate after returning home. eHealth-supported self-management may help sustain AACT gains and prevent post-rehabilitation relapse, though the added value of objective home monitoring devices remains unclear.Methods: In this 12-month pragmatic trial, adults with severe asthma completing AACT in Davos were randomised to eHealth self-management support with or without home monitoring devices measuring airway inflammation, lung function and activity. Randomisation was stratified by baseline fractional exhaled nitric oxide (FeNO; <25 vs ≥25 ppb). The pre-specified primary outcome was time-to-first severe exacerbation; secondary outcomes included annualised exacerbation and hospitalization rates and patient-reported outcomes.Results: Between 2022-2024, 143 patients were randomised; 130 received the allocated intervention (66 intervention, 64 control), and 105 completed follow-up. Time-to-first severe exacerbation did not differ between groups (median [IQR] intervention: 16.5 [13-23], control: 20 [16-30] weeks; log-rank p=0.93). There was a non-significant trend toward fewer annualised severe exacerbations in the intervention group (aRR 0.68, 95%CI 0.45-1.03; p=0.07). Slower ACQ-6 decline (baseline-6 months) was observed in the intervention group (β -0.50, 95%CI -0.95;-0.05; p=0.03), though this did not persist to 12 months. No effect modification by FeNO strata was observed; no intervention-related serious adverse events occurred.Conclusions: Adding home monitoring devices to eHealth self-management did not prolong time-to-first severe exacerbation or sustain clinical benefits after AACT. More personalised, clinically integrated strategies could support the transition to independent self-management.
- Open Access
- 4 March 2026
- Published by Elsevier in Respiratory Medicine
- Vol. 255, 108749
Mapping EQ-5D-5L utility scores from the severe asthma questionnaire in the SHARP CRC registry
- 4 March 2026
- Published by Elsevier in Respiratory Medicine
- Vol. 255, 108749
Open AccessMapping EQ-5D-5L utility scores from the severe asthma questionnaire in the SHARP CRC registry
- Open Access
- 21 November 2025
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 14 (3) , 656-665.e9
Impact of Dupilumab for Severe Asthma on Fatigue, Quality of Life, Work Productivity, and Activity
- 21 November 2025
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 14 (3) , 656-665.e9
Open AccessImpact of Dupilumab for Severe Asthma on Fatigue, Quality of Life, Work Productivity, and Activity
- Open Access
- 1 January 2025
- Published by European Respiratory Society (ERS) in European Respiratory Review
- Vol. 34 (175) , 240122
Patient-centred outcomes in severe asthma: fatigue, sleep, physical activity and work
Severe asthma places a significant burden on patients, with recent research revealing overlooked patient needs extending beyond physical symptoms. To optimise the patient-centred approach to managing severe asthma, it is crucial to deepen our understanding of these needs. This review examines the prevalence and impact of four prioritised patient needs in severe asthma, namely fatigue, sleep disturbances, physical inactivity and reduced presence and productivity at work. It explores how these factors relate to classic asthma outcomes and quality of life, and the potential impact of interventions. Fatigue affects up to 90% of patients, while sleep difficulties impact 70–75% of severe cases, contributing to impaired daily function and quality of life. Although both are linked to asthma control, the cause-and-effect relationship remains unclear, making it clinically intriguing to investigate whether interventions targeting fatigue or sleep problems affect asthma control. In asthma patients, physical inactivity occurs both as consequence and contributing factor to uncontrolled disease. Interventions promoting physical activity improve asthma control and quality of life, suggesting a potential role in severe asthma management. Finally, work productivity loss, notably present in severe asthma cases, strongly correlates with asthma control and exacerbations. While biologic therapies show potential to reverse this loss, their effects on physical activity, fatigue and sleep disturbances warrant further investigation. Nonpharmacological interventions targeting these needs, such as pulmonary rehabilitation and behavioural therapies, may provide opportunities to enhance patients' well-being. Overall, this review highlights significant gaps in understanding patient-centred aspects of severe asthma, urging for research on comprehensive interventions to improve patients' lives.
- 1 January 2025
- Published by European Respiratory Society (ERS) in European Respiratory Review
- Vol. 34 (175) , 240122
Open AccessPatient-centred outcomes in severe asthma: fatigue, sleep, physical activity and work
Severe asthma places a significant burden on patients, with recent research revealing overlooked patient needs extending beyond physical symptoms. To optimise the patient-centred approach to managing severe asthma, it is crucial to deepen our understanding of these needs. This review examines the prevalence and impact of four prioritised patient needs in severe asthma, namely fatigue, sleep disturbances, physical inactivity and reduced presence and productivity at work. It explores how these factors relate to classic asthma outcomes and quality of life, and the potential impact of interventions. Fatigue affects up to 90% of patients, while sleep difficulties impact 70–75% of severe cases, contributing to impaired daily function and quality of life. Although both are linked to asthma control, the cause-and-effect relationship remains unclear, making it clinically intriguing to investigate whether interventions targeting fatigue or sleep problems affect asthma control. In asthma patients, physical inactivity occurs both as consequence and contributing factor to uncontrolled disease. Interventions promoting physical activity improve asthma control and quality of life, suggesting a potential role in severe asthma management. Finally, work productivity loss, notably present in severe asthma cases, strongly correlates with asthma control and exacerbations. While biologic therapies show potential to reverse this loss, their effects on physical activity, fatigue and sleep disturbances warrant further investigation. Nonpharmacological interventions targeting these needs, such as pulmonary rehabilitation and behavioural therapies, may provide opportunities to enhance patients' well-being. Overall, this review highlights significant gaps in understanding patient-centred aspects of severe asthma, urging for research on comprehensive interventions to improve patients' lives.
- 14 September 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 64 (suppl 68) , PA4812
Real-world changes in fatigue in severe asthma patients after starting anti-interleukin-4/13 biologic
Background: Fatigue is highly prevalent in patients with severe asthma and contributes to the disease burden. Dupilumab improves clinical outcomes in severe eosinophilic asthma, but its real-world effect on fatigue is unknown. Aim: To explore changes in fatigue during 12 months after dupilumab initiation in switchers and biologic-naïve patients. Method: Changes in fatigue (CIS-F) and asthma control (ACQ6) were analyzed over 12 months in adult patients who initiated dupilumab and were included in the Dutch severe asthma registry (RAPSODI). Results: Patients (N=243; 44% naïve) had a mean CIS-F score of 38 (12) at baseline, with 63% having severe fatigue (≥36). As compared to baseline, mean decrease on dupilumab was -3.3 (95%CI -4.6 ; -1.9) for fatigue and −0.45 (−0.57 ; −0.34) for ACQ6. Biologic-naïve patients had higher baseline fatigue scores, and larger decreases in fatigue on dupilumab (mean -4.7 (−7.0 ; -2.5)) as compared to switchers (mean -2.5 (−4.13 ; −0.94)) (Fig 1). A similar pattern was shown for ACQ6, with a −0.85 (−1.04 ; −0.66) decrease in naïve patients. After 12 months, 50% of patients still had severe fatigue. Conclusion: Dupilumab treatment is associated with reduced fatigue, with largest effects in biologic-naïve patients. However, clinical significance remains uncertain. Since 50% of patients still had severe fatigue despite biologic treatment, additional interventions should be considered. erj;64/suppl_68/PA4812/F1 F1 F1
- 14 September 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 64 (suppl 68) , PA4812
Real-world changes in fatigue in severe asthma patients after starting anti-interleukin-4/13 biologic
Background: Fatigue is highly prevalent in patients with severe asthma and contributes to the disease burden. Dupilumab improves clinical outcomes in severe eosinophilic asthma, but its real-world effect on fatigue is unknown. Aim: To explore changes in fatigue during 12 months after dupilumab initiation in switchers and biologic-naïve patients. Method: Changes in fatigue (CIS-F) and asthma control (ACQ6) were analyzed over 12 months in adult patients who initiated dupilumab and were included in the Dutch severe asthma registry (RAPSODI). Results: Patients (N=243; 44% naïve) had a mean CIS-F score of 38 (12) at baseline, with 63% having severe fatigue (≥36). As compared to baseline, mean decrease on dupilumab was -3.3 (95%CI -4.6 ; -1.9) for fatigue and −0.45 (−0.57 ; −0.34) for ACQ6. Biologic-naïve patients had higher baseline fatigue scores, and larger decreases in fatigue on dupilumab (mean -4.7 (−7.0 ; -2.5)) as compared to switchers (mean -2.5 (−4.13 ; −0.94)) (Fig 1). A similar pattern was shown for ACQ6, with a −0.85 (−1.04 ; −0.66) decrease in naïve patients. After 12 months, 50% of patients still had severe fatigue. Conclusion: Dupilumab treatment is associated with reduced fatigue, with largest effects in biologic-naïve patients. However, clinical significance remains uncertain. Since 50% of patients still had severe fatigue despite biologic treatment, additional interventions should be considered. erj;64/suppl_68/PA4812/F1 F1 F1
- 14 September 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 64 (suppl 68) , OA4576
The patient health-related quality of life (HRQoL) burden of severe asthma in Europe (SHARP CRC) for specific subgroups
Background: The HRQoL burden for patients with severe asthma is often underappreciated and little is known how this relates to age and sex. The newly validated Severe Asthma Questionnaire (SAQ) has been developed to comprehensively assess HRQoL. Aim: To assess differences in HRQoL burden of severe asthma according to age and sex. Methods: Real-word data from adults in the Severe Heterogeneous Asthma Research Collaboration Patient-centered (SHARP) registry were used in a cross-sectional multivariable linear regression, adjusting for clinical factors. The SAQ consists of a total score and 3 subscales (My Life: impact on life activities; My Mind: emotional impact; My Body: impact on extra-pulmonary symptoms and side effects). Results: Patients (N=208; 57% female, mean age 54(SD 14) yr; 79% biologic use, mean ACQ6-score 1.6(1.3)) had a mean SAQ-score of 5.1(1.6). Women reported lower scores on SAQ and My Body and patients >40yr had higher SAQ-scores across most subscales compared to 60yr exceeded the MCID of 0.5. Conclusion: Compared to men, women with severe asthma report more impact on extra-pulmonary symptoms and side effects. Younger patients seem to have a poorer HRQoL across all aspects than older ones. Insight into drivers of these differences is needed to find ways to optimize HRQoL for everyone. erj;64/suppl_68/OA4576/F1 F1 F1
- 14 September 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 64 (suppl 68) , OA4576
The patient health-related quality of life (HRQoL) burden of severe asthma in Europe (SHARP CRC) for specific subgroups
Background: The HRQoL burden for patients with severe asthma is often underappreciated and little is known how this relates to age and sex. The newly validated Severe Asthma Questionnaire (SAQ) has been developed to comprehensively assess HRQoL. Aim: To assess differences in HRQoL burden of severe asthma according to age and sex. Methods: Real-word data from adults in the Severe Heterogeneous Asthma Research Collaboration Patient-centered (SHARP) registry were used in a cross-sectional multivariable linear regression, adjusting for clinical factors. The SAQ consists of a total score and 3 subscales (My Life: impact on life activities; My Mind: emotional impact; My Body: impact on extra-pulmonary symptoms and side effects). Results: Patients (N=208; 57% female, mean age 54(SD 14) yr; 79% biologic use, mean ACQ6-score 1.6(1.3)) had a mean SAQ-score of 5.1(1.6). Women reported lower scores on SAQ and My Body and patients >40yr had higher SAQ-scores across most subscales compared to 60yr exceeded the MCID of 0.5. Conclusion: Compared to men, women with severe asthma report more impact on extra-pulmonary symptoms and side effects. Younger patients seem to have a poorer HRQoL across all aspects than older ones. Insight into drivers of these differences is needed to find ways to optimize HRQoL for everyone. erj;64/suppl_68/OA4576/F1 F1 F1
- 7 February 2024
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 12 (2) , 534-535
Reply to “Impact of oral corticosteroid on long-term weight following initiation of anti-IL-5/5Ra biologics in severe asthma”
- 7 February 2024
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 12 (2) , 534-535
Reply to “Impact of oral corticosteroid on long-term weight following initiation of anti-IL-5/5Ra biologics in severe asthma”
- Open Access
- 22 December 2023
- Published by Elsevier in Respiratory Medicine
- Vol. 221, 107504
Effect of dietary interventions on markers of type 2 inflammation in asthma: A systematic review
- 22 December 2023
- Published by Elsevier in Respiratory Medicine
- Vol. 221, 107504
Open AccessEffect of dietary interventions on markers of type 2 inflammation in asthma: A systematic review
- 1 December 2023
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
- Vol. 20 (12) , 1825-1828
Effect of Biologic Therapy on Total Body Composition in Severe Asthma
- 1 December 2023
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
- Vol. 20 (12) , 1825-1828
Effect of Biologic Therapy on Total Body Composition in Severe Asthma